Powered by WPeMatico
Mumbai: Smt Nita M Ambani, Founder and Chairperson of Reliance Foundation, announced the launch of a New Health Seva Plan that prioritises essential screenings and treatments for children, adolescent girls and women.
As part of this New Health Seva Plan, Smt. Nita M. Ambani has pledged free screening and treatment for congenital heart disease amongst 50,000 children, free screening and treatment of breast and cervical cancer amongst 50,000 women and free cervical cancer vaccination for 10,000 adolescent girls to commemorate the 10th anniversary of Sir H. N. Reliance Foundation Hospital.
Smt. Nita M. Ambani, Founder and Chairperson of Reliance Foundation, said, “For 10 years, Sir H. N. Reliance Foundation Hospital has been driven by our vision to make world-class healthcare accessible and affordable to every Indian.
Also Read:Sir HN Reliance Foundation Hospital appoints Dr Amit Maydeo as Chairman of Department of Gastroenterology
Together, we have touched millions of lives and offered hope to countless families. As we celebrate this milestone, we have launched a New Health Seva Plan, free of cost, for children and women from marginalized communities. For we believe that good health is the foundation of a prosperous nation, and healthy women and children are the bedrock of a thriving society.”
Sir H. N. Reliance Foundation Hospital has completed a decade of providing exceptional healthcare services. In the past decade, our Hospital has touched the lives of 2.75 million Indians, including over 1.5 lakh children. Sir H. N. Reliance Foundation Hospital is a pioneer in delivering best in class clinical care to its patients, state of the art technology and achieved remarkable milestones in the past decade.
Among the innumerable achievements, Sir H. N. Reliance Foundation Hospital has conducted more than 500 organ transplants, and hold the record for transplanting 6 organs within 24 hours saving multiple lives. Sir H. N. Reliance Foundation Hospital has also been recognized as the No. 1 Multi-Specialty Hospital in India consistently.
Also Read:Mukesh Ambani, family get death threat, caller threatens to blow up Reliance hospital in Mumbai
Powered by WPeMatico
New Delhi: Through a recent notice, the Undergraduate Medical Education Board (UGMEB) of the National Medical Commission (NMC) has asked all the medical colleges/institutes to submit their students’ admission details latest by 8th November 2024 at 12:00 midnight.
The Apex Medical Commission has specified in the notice that beyond this date, the medical colleges/institutes would not be allowed to enter the details of students into the “UG Admission Monitoring Module” Students Entry System for the academic year 2024-2025.
How to Upload Details:
To Navigate the Admission entry page follow the steps as given hereunder:-
• Open NMC Website https://nmc.org.in/ActivitiWebClient/login
• Login using credentials sent by NMC and reset the password if required. Keep the login credentials confidential.
• On the home page click on Student Admission -> New Admission tab
• Three Tabs (UG Admission Entry, PG Broad Admission Entry and PG Super Specialty Admission Entry) will display and you need to click on the “UG Seat/Student Entry” tab.
• The following details about the MBBS students to be entered by the colleges.
• Seat Entry
a. Category of the College (Govt. / Private/Other)
b. Minority/ Non Minority
c. Name of the Counselling authority through which admission made.
d. Seat Matrix If Private College (Upload consensual agreement with the Government)
Students Details Entry:
i. Entrance exam (NEET) Roll No.
The following details will appear auto-populated after entering NEET Roll No. (which should be verified by the college)
a) Name of Student
b) Merit No./All India Rank/State Rank
c) Gender (Male/Female/Others
d) Date of Birth in dd/mm/yyyy format
e) Sub Category (ST/SC/OBC/Unreserved)
f) Physically handicapped (Yes/No)
ii. Category (All India quota/State Government or UT Administration quota/Management quota/NRI quota/ Other)
iii. Date of Admission in dd/mm/yyyy format
iv. Marks Obtained /Maximum marks in PCB (10+2)
v. Marks Obtained /Maximum marks in English (10+2)
vi. Marks Obtained /Maximum marks in PCB entrance exam (NEET) and percentile
vii. Fees charged from student annually (Amount is Rupees)
“Kindly add the details of the Students according to the fields as mentioned above which will be available on the screen. No modification will be allowed after the cutoff date,” the UG Board of NMC mentioned in the notice.
“The Colleges should also ensure that the following details with regard to S. No. (1 to 22) mentioned below regarding the admitted students should be mandatorily available on the college website. The Commission may ask other supportive documents like Caste certificate, 10+2 mark sheet, details of Competitive entrance exam, as and when required by the Monitoring Cell. Students, who have 10+2 from outside India, are required to submit equivalence certificate issued by Association of Indian Universities stating that the academic credentials are as per the Curriculum of Indian System,” the Commission added.
The colleges will have to ensure that the details including the serial number, merit number, name of the student, if physically handicapped or not, date of birth, category, sub-category, marks obtained in 10+2(PCB), maximum marks in 10+2 (PCB), PCB percentage, marks obtained in 10_2(english), maximum marks in 10+2(eng), English Percentage, entrance exam name, marks obtained in entrance exam, maximum marks in entrance exam, entrance exam percentage, date of admission, entrance percentage/percentile, NEET Roll number, fees charged etc. are available on the college website.
NMC launched an online monitoring system to effectively monitor that all MBBS admissions are made in conformity with the requirements of Regulations. This initiative is made with the objective of ensuring faithful adherence to the norms of admission laid down in Regulations as also to further promote transparency and accountability in the medical education.
“Therefore, all the Medical Colleges/Institutions are called upon to submit the requisite information through an online system that can be accessed through Commission’s website [http://www.nmc.org.in]. The college authorities are required to submit the details of all the Students admitted for MBBS during the current academic year 2024-25,” the UG Board of NMC mentioned in the notice.
“Through this unique login id all the Medical colleges/Institutions must submit their student’s admission details latest by 8th November, 2024 12:00 pm midnight into “ beyond which the Colleges/Institutions will not be allowed to enter the details of the students into “UG Admission Monitoring Module” Students Entry System for academic year 2024-25,” it mentioned, further adding that the “onus of furnishing true, correct and authentic information is upon the College concerned.”
As per the notice, NMC shall initiate action as is permissible in law, if it is notified that wrong/incorrect information has been provided by the College authorities. In case of any difficulty in accessing NMC website/data entry, an email may be sent to support.ugmonitoring@nmc.org.in NMC office shall revert immediately to resolve the query/issue.
MBBS Admissions Must be Made in Accordance with the Provisions of the NMC Act 2019:
The Apex Medical Commission further highlighted in the notice that admissions in MBBS course for the academic year 2024-2025 must be made in accordance with the provisions of the National Medical Commission Act, 2019, and the National Eligibility -Entrance Test (NEET) based selection process notified by the Graduate Medical Education Regulation 2024.
While granting admission in MBBS course the Medical Colleges are required to ensure that the admission is in terms of the following parameters, based upon the NMC Regulations:-
(i) No Admission is permissible beyond the sanctioned intake capacity.
(ii) Eligibility Criteria regarding age and Qualifying Marks for different categories as per Regulations on Graduate Medical Education, 2024.
•Completed the age of 17 years on or before the 31st December of the year of admission to the MBBS course.
• Must have passed the Qualifying Examination i.e. 10+2.
(iii) Must have qualified NEET-UG (National Eligibility – Entrance Test for admission in MBBS course.
• General Category: 50th percentile or above.
• Physically Handicapped: 45th percentile or above.
• Reserved {SC/ST/OBC}: 40th percentile or above.
(iv) All admissions have to be made through common counseling as prescribed in Regulations mentioned below.
Common Counseling:
(1) There shall be a common counseling for admission to MBBS course in all Medical Educational Institutions on the basis of merit list of the National Eligibility Entrance Test.
(2) The Designated Authority for counseling for the 15% All India Quota seats of the contributing States and all MBBS seats of Medical Educational Institutions of the Central Government, Universities established by an Act of Parliament and the Deemed Universities shall be the Directorate General of Health Services, Ministry of Health and Family Welfare, Government of India.
(3) The counseling for admission to MBBS course in a State/Union Territory, including, Medical Educational Institutions established by the State Government, University established by an Act of State/Union Territory Legislature, Trust, Society, Minority Institutions, Municipal Bodies or a Company shall be conducted by the State/Union Territory Government.
“The Medical Colleges are required to ensure that all admission in courses of medicine falling within the purview of the NMC Act, 2019 are strictly in accordance with merit and are made in a transparent and fair manner as envisaged in the Regulations. Any violation shall lead to discharge of the students from the MBBS programme and action against the concerned Medical College/Institution as is permissible in law,” NMC further added in the notice.
Graduate Medical Education Regulations, 2023:
As per Graduate Medical Education Regulation, 2023 dated 02.06.2023, in respect of the admission procedure in MBBS course, clear guidelines are stated as under:
“16.The prohibition for any student seeking admission any other way than counselling – No medical institute shall admit any candidate to the Graduate Medical Education course in contravention of these regulations;
Provided the Medical Institution granting admission to any student in contravention of these Regulations, shall be liable to be fined Rupees one crore or fee for the entire course duration, whichever is higher, per seat for the first time and for the second time of non-compliance, Rupees two crore or double the amount of fees for the entire course duration whichever is higher per seat, and for any subsequent non-compliance or continued contravention the Medical Institution shall be barred from granting admissions to any student from the next academic year;
Provided further that such Student admitted in contravention of this mandate shall be discharged from the Medical College and double the number of seats shall be reduced for one or more years.”
Referring to these rules, the UG Board of NMC mentioned in the notice, “In light of abovementioned regulation, no admission shall be carried out by university/ medical colleges/ institutes or any unauthorized agency (through offline and online mode). If any deviation in regard to the above regulation is found, strict actions shall be initiated by the NMC in accordance with the above regulations.”
Sharing the notice, NMC Secretary Prof B Srinivas mentioned in a notice dated 29.10.2024, “Reference is cited to Circular no. U-16011/Circular/2024- 25/UGMEB/M.Cell dated 22-10-2024 issued by the Under Graduate Medical Education Board (UGMEB) on the subject mentioned above enclosed herewith. All concerned stakeholders are requested to kindly take note of the same.”
To view the NMC notice, click on the link below:
https://medicaldialogues.in/pdf_upload/ugmeb-circular-dtd-29-10-2024-258917.pdf
Also Read: MBBS Admissions not uploaded on the NMC Portal will be considered INVALID
Powered by WPeMatico
Thermo FisherScientific has announced the signing of a
Memorandum of Understanding (MoU) with the Government of Telangana to establish
a Bioprocess Design Centre (BDC) in Genome Valley, Hyderabad.
Joining them was the
senior leadership team from Thermo Fisher Scientific, including Fred Lowery,
Executive Vice President & President, Lab Products and BioProduction, Daniella
Cramp, Sr. Vice President & President, BioProduction, Tony Acciarito,
President, APJ, Srinath Venkatesh, Managing Director, India & South Asia and
Sarita Rawat, Sr. Director, Bio Production & Corporate Accounts.
“Totalling
10,000 sq. ft., the Bioprocess Design Centre will become operational in early
2025 and serve as a benchmark to accelerate the development and manufacturing
of innovative biotherapeutics in India and Asia-Pacific region,” the Company stated. The Centre will
feature state-of-the-art labs as well as training hubs to drive scientific research.
Shri
Duddilla Sridhar Babu,
Minister for ITE&C and I&C Departments, commented, “Telangana has
consistently demonstrated its commitment to fostering innovation and nurturing
world-class ecosystems for biotech and life sciences industries. The
establishment of this Bioprocess Design Centre reflects the state’s progressive
policies and collaborative approach to building a robust biopharma
infrastructure. With over 1,800 companies, Telangana is leading the way in
making India a global hub for biopharma innovation. We are thrilled to partner
with Thermo Fisher, the world leader in serving science, in this transformative
initiative that will advance the future of healthcare.”
Shakthi
Nagappan,
Director of Lifesciences and Pharma, Government of Telangana, stated, “This
partnership with Thermo Fisher marks a significant milestone in our efforts to
build a first-of-its-kind bioprocessing facility for biologics manufacturing in
India. The centre, featuring single-use bioreactors, will enhance the biopharma
sector by offering pay-per-use infrastructure, technical expertise, and
cutting-edge research solutions, helping companies reduce their time to market.
It will not only drive the growth of biopharma manufacturing in Telangana but
also bolster India’s position on the global map.”
Thermo
Fisher will equip the centre with advanced workflow capabilities across
upstream and downstream research, cell culture media development, single-use
scale-up manufacturing, and product validation.
Speaking
on the occasion, Daniella Cramp, Sr. Vice President & President, BioProduction,
Thermo Fisher Scientific said, “I sincerely thank
the Government of Telangana for partnering with Thermo Fisher and supporting
our Mission. This state-of-the-art
facility will enable academic researchers, biopharma start-ups and companies to
fast-track their innovations by meeting their end-to-research and manufacturing
needs.”
Srinath
Venkatesh,
Managing Director, India & South Asia, Thermo Fisher Scientific, said,
“India is fast emerging as a global biopharma hub, with significant growth in
research and development driven by key pharmaceutical and biotech companies.
The Bioprocess Design Centre underscores our commitment to empowering our
customers through technological advancements. By focusing on areas like
oncology, cell and gene therapies, and biotherapeutics, we aim to drive
breakthroughs for a healthier world.”
Hyderabad
is recognized as the new destination for large biotech and life sciences
companies due to enabling government policies and industrial practices, infrastructure
facilities and a diverse talent ecosystem of skilled professionals in
chemistry, biology, genetics, technology and beyond.
Thermo
Fisher has a state-of-the-art R&D and engineering
centre in Hyderabad for supporting product designing, development, reliability
performance testing and verification, as well as validation of products.
Earlier
this year, Thermo Fisher also partnered with leading bio-incubators to set up
five Centres for Innovation at Centre for Cellular
and Molecular Platforms (C-CAMP), Bengaluru, Atal Incubation Centre – Centre
for Cellular Molecular Biology (AIC-CMB), Hyderabad, Aspire Bionest, Hyderabad,
IIT Bionest, Guwahati and KIIT-TBI, Bhubaneshwar. These centres are providing
start-ups access to Thermo Fisher’s advanced technologies and expertise,
significantly reducing the time to market for new biopharma products.
Read also: Bayer, Thermo Fisher Scientific join hands to increase patient access to precision cancer medicines
Powered by WPeMatico
Powered by WPeMatico
USA: Recent research has unveiled a concerning connection between urinary calcium excretion and bone health in youth diagnosed with Type 1 Diabetes (T1D). The study, published in The Journal of Clinical Endocrinology & Metabolism, indicates that elevated levels of urinary calcium may hinder bone accrual, raising alarms about the long-term skeletal health of these young individuals.
“Youths with Type 1 Diabetes demonstrated lower bone mineral accrual than their peers without the condition. Additionally, higher urinary calcium excretion was associated with reduced bone accrual,” the researchers wrote.
Type 1 Diabetes, an autoimmune condition primarily affecting insulin production, has been associated with various complications, including metabolic and skeletal issues. The negative impact of T1D on skeletal health encompasses insufficient bone accrual and a heightened risk of fractures throughout life. However, the factors that lead to impaired bone development in individuals with T1D remain partially unclear.
Against the above background, David R Weber, Department of Pediatrics, The Children’s Hospital of Philadelphia and The Perelman School of Medicine at the University of Pennsylvania, Philadelphia, USA, and colleagues aimed to investigate whether urinary calcium excretion is linked to impaired bone accrual in youth with Type 1 Diabetes, and assess how glycemic control and markers of bone mineral metabolism contribute to urinary calcium levels.
For this purpose, the researchers conducted an observational study involving fifty participants aged 6 to 20 years with Type 1 Diabetes who completed a 12-month longitudinal examination of bone accrual. Additionally, a second cohort of 99 similarly aged individuals with T1D participated in cross-sectional 24-hour urine and blood collections. The primary outcome measures were the velocity Z-score of the whole body less head bone mineral content (WBLH BMC) and the fractional excretion of calcium (FeCa).
The following were the key findings of the study:
The findings showed that urinary calcium excretion was negatively correlated with bone accrual in the cohort of youths with type 1 diabetes.
“Further mechanistic studies are required to explore whether interventions aimed at reducing urinary calcium excretion could enhance bone accrual and decrease skeletal fragility in individuals with T1D,” the researchers concluded.
Reference:
Weber, D. R., O, K., Ballester, L., Rackovsky, N., Graulich, B., & Schwartz, G. J. Greater Urinary Calcium Excretion Is Associated With Diminished Bone Accrual in Youth With Type 1 Diabetes. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgae660
Powered by WPeMatico
Findings from the TAVR UNLOAD study found limited benefits of transcatheter aortic valve replacement (TAVR) in the treatment of heart failure (HF) with reduced ejection fraction (HFrEF) and moderate aortic stenosis (AS).
Findings were reported today at TCT 2024, the annual scientific symposium of the Cardiovascular Research Foundation (CRF). TCT is the world’s premier educational meeting specializing in interventional cardiovascular medicine. The results were also published simultaneously in the Journal of the American College of Cardiology.
Medical neurohormonal modulation and afterload reduction are key elements in the treatment of HFrEF. In patients with HFrEF and moderate AS, a complementary target for afterload reduction may be treatment of the AS. However, current guidelines recommend TAVR for symptomatic severe AS or for asymptomatic severe AS with left ventricular (LV) ejection fraction <50% but not for moderate AS.
The investigator-initiated, international, randomized controlled trial enrolled patients with NYHA class II-IV HFrEF (LV ejection fraction ≥20% and <50%) and moderate AS (aortic valve area >1.0 cm2 and ≤1.5 cm2) who were suitable for transfemoral TAVR with a balloon-expandable valve. From January 2017 to December 2022, 178 patients at 66 institutions in the United States, Netherlands and Austria were randomized 1:1 to TAVR and guideline-directed medical therapy (n=89) or guideline-directed medical therapy alone (n=89). The mean age of participants was 77 years, 20.8% were female and 55.6% were in NYHA class III or IV. The mean LV ejection fraction was 39%. During the study, 39% (n=35) of those in the medical therapy group progressed from moderate to severe AS.
The original study design required 600 patients (two groups of 300) with a primary endpoint analysis at one year. However, an updated protocol allowed for the use of the longest available follow-up data, justifying a reduced sample size of 300 patients (2 groups of 150). Due to funding limitations and slow enrollment, the Steering Committee decided to terminate enrollment by December 31, 2022, ensuring at least one year of follow-up for all participants.
The primary end point was the hierarchical occurrence of all-cause death, disabling stroke, disease-related hospitalizations, and HF equivalents, as well as the change from baseline in the Kansas City Cardiomyopathy Questionnaire Overall Summary score (KCCQ-OS). At one year, TAVR resulted in more wins driven by clinically meaningful improvement in quality of life compared with clinical AS surveillance [Win Ratio = 1.55 (1.04-2.31), p=0.032]. However, TAVR did not affect the primary composite endpoint at a median follow up of 23 months [Win Ratio = 1.31 (0.91-1.88), p=0.143]. In addition, MACCE [Hazard Ratio 0.83 (95% CI, 0.56-1.24, p=0.36)] and all-cause death [Hazard Ratio 0.98 (95% CI, 0.61-1.56, p=0.92)] were not significant between the two groups.
“Although TAVR for moderate aortic stenosis in patients with systolic heart failure on guideline-directed medical therapy was safe, it did not affect the primary hierarchical composite endpoint at a median follow up of 23 months,” said Nicolas M. Van Mieghem, MD, PhD, Professor and Clinical Director of Interventional Cardiology, Department of Cardiology, Cardiovascular Institute, Thoraxcenter Erasmus University Medical Center. “During the trial, more than 40 percent of the surveillance group underwent TAVR predominantly because of disease progression from moderate to severe aortic stenosis, which is more than we anticipated. The cardiac damage framework may identify a broader patient phenotype with moderate aortic stenosis that may benefit from upstream TAVR and is currently under investigation in other trials.”
Reference:
Transcatheter aortic valve replacement in patients with systolic heart failure and moderate aortic stenosis shows limited benefits, Cardiovascular Research Foundation, Meeting: TCT 2024: Transcatheter Cardiovascular Therapeutics.
Powered by WPeMatico
A new study published in the journal of Clinical and Experimental Allergy showed that the combination of allergen immunotherapy (AIT) with biologics provides extremely promising new therapy methods for the management of allergic asthma in individuals with severe asthma or other safety concerns.
Over 350 million people throughout the globe suffer from asthma that causes 0.4 million deaths annually and is becoming increasingly common. In order to provide individualized treatments, the so-called “asthma endotypes” have been defined in light of the disease’s complexity and heterogeneity. There are two main subtypes of asthma namely Th2-low, also known as type 2-low or “non-type 2 asthma,” and Th2-high, often known as type 2-high asthma or simply “type 2 asthma.” In addition to the differences between type 2 and non-type 2 asthma, the latter includes eosinophilic and/or allergic asthma.
Biological treatments have helped some uncontrolled asthmatic patients in recent decades, particularly the ones with allergic asthma. However, not all of the unmet requirements left by traditional pharmacotherapy are covered by biologics. It is also important to highlight that neither biological treatments nor traditional medication have the ability to alter illness. Because of its disease-modifying immunological effects, allergen immunotherapy is a vital part of the treatment arsenal against allergic asthma.
This study initially examined how traditional pharmacotherapy is used to treat asthma and noted the shortcomings of this approach in treating more severe cases of the condition. They then discussed how biological treatments may be used to control the latter and what requirements they have yet to address. The advantages of allergen immunotherapy, either alone or in conjunction with traditional pharmacotherapy and/or biological therapy in the treatment of allergic asthma from both a preventative and therapeutic standpoint were finally reviewed, adhering to the approach outlined in Data S1.
The study found that the sole disease-modifying method for treating allergies is AIT. Numerous studies demonstrate its advantages in treating and controlling asthma, including RDBPC clinical trials. In the individuals with allergic rhinitis, it can stop the condition from developing into allergic asthma. When allergic asthma has been diagnosed, AIT can either help the patient or at least stop the problem from getting worse. As a result of its conjunction with biological therapy, there is a growing chance that more patients may benefit from its effects. Overall, allergen immunotherapy treats illness by targeting IgE-mediated allergies that provides benefits which extend beyond symptomatic relief.
Reference:
Batard, T., Taillé, C., Guilleminault, L., Bozek, A., Floch, V. B., Pfaar, O., Canonica, W. G., Akdis, C., Shamji, M. H., & Mascarell, L. (2024). Allergen Immunotherapy for the Prevention and Treatment of Asthma. In Clinical & Experimental Allergy. Wiley. https://doi.org/10.1111/cea.14575
Powered by WPeMatico
A new study published in the journal of Molecular Psychiatry found that heparin medication was linked to a delayed diagnosis of Alzheimer’s dementia. Recent data indicated that the relationship between APOE and heparan sulphate proteoglycans (HSPGs) may have bearing on Alzheimer’s disease (AD) susceptibility, defense and possible prevention and therapy. It also has a very low affinity for the rare ApoE Christchurch variant, which was linked to a very low risk of AD dementia in a carrier of Presenilin 1 (PSEN1).
A typical anticoagulant medication is heparin, a hyper-sulfated form of heparan sulphate that is present in mast cells. When unfractionated heparin (UFH), a minimally processed version of naturally produced heparin, was first used in clinical settings in the 1930s, it marked a significant advancement in medicine. In addition to managing coagulation during procedures like cardiac surgery, dialysis, or extracorporeal circulation,
UFH and low molecular weight heparin (LMWH) are commonly used to treat and prevent thrombotic events like atrial fibrillation (AF), deep vein thrombosis (DVT), and pulmonary embolism (PE). Benjamin Readhead and colleagues investigated whether heparin medication was linked to a delayed diagnosis of AD dementia using electronic health records (EHR) from two distinct health systems.
Individuals who received or did not receive heparin therapy had at least 5 years of observation and were at least 65 years old at the time of their last visit with subsequent diagnostic code or drug treatment evidence of possible AD dementia. They were compared using longitudinal EHR data from 15,183 patients from the Mount Sinai Health System (MSHS) and 6207 patients from Columbia University Medical Centre (CUMC) in separate survival analyses. Age, sex, comorbidities, length of follow-up, and number of inpatient stays were all taken into account in the analyses.
Significant delays in the age at which AD dementia was clinically diagnosed were linked to heparin medication. These delays included +1.0 years in the MSMS cohort (P < 0.001) and +1.0 years in the CUMC cohort (P < 0.001). This data supports the possible functions of heparin-like medications and HSPGs in preventing and protecting against AD dementia, even if further research is required. Overall, the results of this study suggest that heparin treatment may have a preventive effect against the eventual onset of AD. These results may help guide the design of next research to look into the link in depth.
Reference:
Readhead, B., Klang, E., Gisladottir, U., Vandromme, M., Li, L., Quiroz, Y. T., Arboleda-Velasquez, J. F., Dudley, J. T., Tatonetti, N. P., Glicksberg, B. S., & Reiman, E. M. (2024). Heparin treatment is associated with a delayed diagnosis of Alzheimer’s dementia in electronic health records from two large United States health systems. In Molecular Psychiatry. Springer Science and Business Media LLC. https://doi.org/10.1038/s41380-024-02757-5
Powered by WPeMatico
A study published in JAMA suggests that hidradenitis suppurativa is linked to adverse maternal and offspring outcomes in the peripartum period and in the long term.
Hidradenitis suppurativa (HS) is associated with morbidity in persons of reproductive age, but the effect on maternal and offspring outcomes is understudied.
A study was done to determine the association of HS with pregnancy outcomes and maternal and child morbidity in the long term. This population-based longitudinal cohort study with up to 16 years of follow-up took place between 2006 and 2022 in Quebec, Canada. Outcomes included hypertensive disorders of pregnancy, gestational diabetes, and other birth outcomes as well as the long-term risk of hospitalization up to 16 years after delivery. The study used adjusted log-binomial and Cox proportional hazards regression models to estimate the association between maternal HS and pregnancy outcomes or hospitalization following pregnancy. Outcomes in both mothers and offspring were assessed. Results There were 1 324 488 deliveries during the study, including 1332 (0.1%) among mothers with HS. Compared with patients without HS, patients with HS had a greater risk of hypertensive disorders of pregnancy (risk ratio [RR], 1.55 [95% CI, 1.29-1.87]), gestational diabetes (RR, 1.61 [95% CI, 1.40-1.85]), and severe maternal morbidity (RR, 1.38 [95% CI, 1.03-1.84]). In neonates, maternal HS was associated with risk of preterm birth (RR, 1.28 [95% CI, 1.07-1.53]) and birth defects (RR, 1.29 [95% CI, 1.07-1.56]). In the long term, HS was associated with 2.29 times the risk of maternal hospitalization (95% CI, 2.07-2.55) and 1.31 times the risk of childhood hospitalization (95% CI, 1.18-1.45), including hospitalization for respiratory, metabolic, psychiatric, and immune-related morbidity over time. This cohort study found that HS is associated with adverse maternal and offspring outcomes in the peripartum period and in the long term. Early detection and management of HS may help mitigate these outcomes.
Reference:
Li K, Piguet V, Croitoru D, et al. Hidradenitis Suppurativa and Maternal and Offspring Outcomes. JAMA Dermatol. Published online October 16, 2024. doi:10.1001/jamadermatol.2024.3584
Keywords:
Hidradenitis, suppurativa, linked, adverse, maternal, offspring, outcomes, peripartum, period, long term, JAMA, Li K, Piguet V, Croitoru D
Powered by WPeMatico